Neurotoxicity of immunosuppressive drugs
- 1 November 2001
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 7 (11), 937-942
- https://doi.org/10.1053/jlts.2001.27475
Abstract
The clinical profile of neurotoxicity caused by immunosuppression has changed. When toxic levels are reached, both cyclosporine and tacrolimus may produce a clinical spectrum that varies from tremor and acute confusional state to status epilepticus and major speech or language abnormalities. Coma has become an unusual manifestation. Magnetic resonance imaging has been better defined, and abnormalities may be more widespread than those in the posterior lobes. These white matter lesions are caused by vasogenic edema, but may lead to apoptosis and cytotoxic edema if exposure is prolonged. Recent evidence suggests inhibition of a drug-efflux pump and dysfunction of the blood-brain barrier by enhanced nitric oxide production.This publication has 40 references indexed in Scilit:
- Neurotoxicity of calcineurin inhibitors: impact and clinical managementTransplant International, 2000
- CONVERSION TO NEORAL FOR NEUROTOXICITY AFTER PRIMARY ADULT LIVER TRANSPLANTATION UNDER TACROLIMUS 1Transplantation, 2000
- Neurologic complications of pediatric lung transplantationNeurology, 1999
- Oral cyclosporine decreases severity of neurotoxicity in liver transplant recipientsNeurology, 1999
- Immunosuppressants, immunophilins, and the nervous systemAnnals of Neurology, 1996
- A New Microemulsion Formulation of CyclosporinClinical Pharmacokinetics, 1996
- Neurotoxicity in liver transplant recipients with cyclosporine immunosuppressionNeurology, 1995
- Tacrolimus, a New Immunosuppressant—A Review of the LiteratureAnnals of Pharmacotherapy, 1994
- FK506‐induced neurotoxicity in liver transplantationAnnals of Neurology, 1994
- Central Nervous System Toxicity after Liver TransplantationNew England Journal of Medicine, 1987